A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Enrollment Completed In ONWARD’s LIFT Home Study

Enrollment Completed in ONWARD’s LIFT Home Study Study Evaluates Safety and Performance of ARCEX Therapy for Spinal Cord Injury in Home Setting

ONWARD Medical N.V. today announced the completion of enrollment in the LIFT Home Study. The trial is designed to study the safety and performance of ARCEX Therapy when used in the home.

ONWARD’s ARCEX Therapy is externally delivered programmed stimulation of the spinal cord to restore strength and function in people with spinal cord injury and other movement related challenges. The study enrolled 17 participants at 5 leading research centers in the United States: Craig Hospital in Denver, Colorado, Shepherd Center in Atlanta, Georgia, Spaulding Research Institute in Boston, Massachusetts, University of Minnesota, and University of Washington. Subjects were followed for four weeks to assess whether continued access to ONWARD’s ARCEX Therapy is safe and can be used to enhance long-term benefit.

Candy Tefertiller, PT, DPT, Ph.D., NCS, Executive Director of Research and Evaluation at Denver’s Craig Hospital served as Primary Investigator. “The LIFT Home Study is an important next step in understanding the potential benefits people with spinal cord injury may derive from continued access to ARC Therapy outside the clinic,” said Dr. Tefertiller. ”We are pleased enrollment is now complete and we look forward to completing follow-up activities.”

The LIFT Home Study is a successor to ONWARD’s Up-LIFT Study, a pivotal trial that completed enrollment of 65 participants in December 2021, with participating research centers in the US, Canada, the UK, and Europe. Up-LIFT is designed to demonstrate ONWARD ARCEX Therapy can improve the strength and function of upper limbs when used in the rehabilitation clinic setting. The LIFT Home Study seeks to evaluate the potential impact of ARCEX Therapy when used in the home setting.

“We are grateful to collaborate with these outstanding researchers to investigate new potential benefits and care settings for our ARCEX Therapy,” said Dave Marver, CEO of ONWARD. “This is another step in our journey to help people with spinal cord injury regain function and independence.”

SourceONWARD
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy